Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386423335> ?p ?o ?g. }
- W4386423335 endingPage "2277" @default.
- W4386423335 startingPage "2277" @default.
- W4386423335 abstract "Mirabegron (MBR) is a β3-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (F), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous dispersions of MBR, such as MBR-1,2-ethanedisulfonic acid (MBR-EFA), MBR-1,5-naphthalenedisulfonic acid (MBR-NDA), and MBR-L-pyroglutamic acid (MBR-PG), have been developed, showing improved solubility and thermodynamic stability. Nevertheless, the pharmacokinetic feasibility of these co-amorphous dispersions has not been evaluated. Therefore, this study aimed to characterize the pharmacokinetic profiles of MBR-EFA, MBR-NDA, and MBR-PG in rats and mice. Our results exhibited that relative F24h and AUC0–24h values of MBR in MBR-EFA, MBR-NDA, and MBR-PG rats were increased by 143–195% compared with the MBR rats. The absolute F24h, relative F24h, and AUC0–24h values of MBR in MBR-EFA and MBR-NDA mice were enhanced by 178–234% compared with the MBR mice. In tissue distribution, MBR was extensively distributed in the gastrointestinal tract, liver, kidneys, lung, and heart of mice. Notably, MBR distribution in the liver, kidneys, and lung was considerably high in MBR-EFA, MBR-NDA, or MBR-PG mice compared with MBR mice. These findings highlight the potential of these co-amorphous dispersions to enhance oral F of MBR." @default.
- W4386423335 created "2023-09-05" @default.
- W4386423335 creator A5014052592 @default.
- W4386423335 creator A5026860974 @default.
- W4386423335 creator A5039986835 @default.
- W4386423335 creator A5047343338 @default.
- W4386423335 creator A5060549316 @default.
- W4386423335 creator A5068635994 @default.
- W4386423335 date "2023-09-04" @default.
- W4386423335 modified "2023-10-17" @default.
- W4386423335 title "Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice" @default.
- W4386423335 cites W152943885 @default.
- W4386423335 cites W1541736117 @default.
- W4386423335 cites W1917380911 @default.
- W4386423335 cites W1963810625 @default.
- W4386423335 cites W1964819068 @default.
- W4386423335 cites W1967105697 @default.
- W4386423335 cites W1967935934 @default.
- W4386423335 cites W1975146065 @default.
- W4386423335 cites W1990628551 @default.
- W4386423335 cites W2000092715 @default.
- W4386423335 cites W2005790995 @default.
- W4386423335 cites W2012306132 @default.
- W4386423335 cites W2025412733 @default.
- W4386423335 cites W2034177400 @default.
- W4386423335 cites W2040432233 @default.
- W4386423335 cites W2044146593 @default.
- W4386423335 cites W2044594845 @default.
- W4386423335 cites W2047195572 @default.
- W4386423335 cites W2064705056 @default.
- W4386423335 cites W2070719925 @default.
- W4386423335 cites W2075179133 @default.
- W4386423335 cites W2078814811 @default.
- W4386423335 cites W2096105051 @default.
- W4386423335 cites W2104833374 @default.
- W4386423335 cites W2131449169 @default.
- W4386423335 cites W2138057956 @default.
- W4386423335 cites W2155223429 @default.
- W4386423335 cites W2158637106 @default.
- W4386423335 cites W2160700727 @default.
- W4386423335 cites W2228474836 @default.
- W4386423335 cites W2275521990 @default.
- W4386423335 cites W2333656544 @default.
- W4386423335 cites W2506880365 @default.
- W4386423335 cites W2591345659 @default.
- W4386423335 cites W2773037751 @default.
- W4386423335 cites W2791701254 @default.
- W4386423335 cites W2791734274 @default.
- W4386423335 cites W2800933213 @default.
- W4386423335 cites W2890816104 @default.
- W4386423335 cites W2921543352 @default.
- W4386423335 cites W2936164606 @default.
- W4386423335 cites W2938114707 @default.
- W4386423335 cites W2946859015 @default.
- W4386423335 cites W2955461563 @default.
- W4386423335 cites W2965134647 @default.
- W4386423335 cites W3088576329 @default.
- W4386423335 cites W3112948256 @default.
- W4386423335 cites W3121499557 @default.
- W4386423335 cites W3124291728 @default.
- W4386423335 cites W3139112345 @default.
- W4386423335 cites W4221044788 @default.
- W4386423335 cites W4323857824 @default.
- W4386423335 cites W4367599166 @default.
- W4386423335 doi "https://doi.org/10.3390/pharmaceutics15092277" @default.
- W4386423335 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37765246" @default.
- W4386423335 hasPublicationYear "2023" @default.
- W4386423335 type Work @default.
- W4386423335 citedByCount "0" @default.
- W4386423335 crossrefType "journal-article" @default.
- W4386423335 hasAuthorship W4386423335A5014052592 @default.
- W4386423335 hasAuthorship W4386423335A5026860974 @default.
- W4386423335 hasAuthorship W4386423335A5039986835 @default.
- W4386423335 hasAuthorship W4386423335A5047343338 @default.
- W4386423335 hasAuthorship W4386423335A5060549316 @default.
- W4386423335 hasAuthorship W4386423335A5068635994 @default.
- W4386423335 hasBestOaLocation W43864233351 @default.
- W4386423335 hasConcept C142724271 @default.
- W4386423335 hasConcept C181389837 @default.
- W4386423335 hasConcept C185592680 @default.
- W4386423335 hasConcept C204787440 @default.
- W4386423335 hasConcept C2778164427 @default.
- W4386423335 hasConcept C2778941218 @default.
- W4386423335 hasConcept C43617362 @default.
- W4386423335 hasConcept C71924100 @default.
- W4386423335 hasConcept C98274493 @default.
- W4386423335 hasConceptScore W4386423335C142724271 @default.
- W4386423335 hasConceptScore W4386423335C181389837 @default.
- W4386423335 hasConceptScore W4386423335C185592680 @default.
- W4386423335 hasConceptScore W4386423335C204787440 @default.
- W4386423335 hasConceptScore W4386423335C2778164427 @default.
- W4386423335 hasConceptScore W4386423335C2778941218 @default.
- W4386423335 hasConceptScore W4386423335C43617362 @default.
- W4386423335 hasConceptScore W4386423335C71924100 @default.
- W4386423335 hasConceptScore W4386423335C98274493 @default.
- W4386423335 hasIssue "9" @default.
- W4386423335 hasLocation W43864233351 @default.
- W4386423335 hasLocation W43864233352 @default.